GlassScriptPhysician profile
Seema Patil
NPI 1285816173
$9,266.04
in general payments reported to CMS, 2019-2025
23 companies · $1,225 in 2025
The $1,225 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $69.92 · 2021: $187 · 2022: $1,060 · 2023: $1,129 · 2024: $5,456 · 2025: $1,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,170 · Food and Beverage: $3,591 · Travel and Lodging: $48.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,170.00 |
| Food and Beverage | $3,591.17 |
| Travel and Lodging | $48.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,399.10 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $768.27 | 2022-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $597.16 | 2022-2025 | |
| Celgene Corporation | $420.48 | 2022-2024 | Zeposia |
| Pfizer INC. | $318.88 | 2021-2025 | |
| Madrigal Pharmaceuticals | $170.97 | 2025 | Rezdiffra |
| Medtronic, INC. | $146.11 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.89 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $47.39 | 2024 | Omvoh |
| Mallinckrodt Hospital Products INC. | $39.36 | 2023 | Terlivaz |
| Genzyme Corporation | $37.11 | 2023 | |
| Janssen Scientific Affairs, LLC | $33.84 | 2025 | Tremfya |
| Amgen INC. | $30.46 | 2023 | Avsola, Amjevita |
| Alnylam Pharmaceuticals INC. | $29.67 | 2020 | |
| Celltrion USA INC. | $27.74 | 2025 | Vegzelma |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $23.24 | 2025 | Iqirvo |
| Shionogi INC | $20.83 | 2019 | |
| Organon LLC | $20.57 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.44 | 2025 | Voquezna |
| W. L. Gore & Associates, INC. | $17.66 | 2023 | Gore Cardioform Septal Occluder |
| Sandoz INC. | $16.87 | 2023 | Hyrimoz |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.